CAC 40
8 022,41 -0,85 (-0,01 %) Euro Stoxx 50
4 918,09 -18,48 (-0,37 %) Dow Jones
37 986,40 +211,02 (+0,56 %) EUR/USD
1,0656 +0,0010 (+0,10 %) Gold future
2 403,20 +5,20 (+0,22 %) Bitcoin EUR
60 212,41 +736,86 (+1,24 %)
Moderna, Inc. (MRNA)
Échanges après Bourse :
Moderna, Inc.
200 Technology Square
Cambridge, MA 02139
United States
617 714 6500
https://www.modernatx.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 5 600
Dirigeants clés
| Nom | Titre | Payer | Exercé | Année de naissance |
|---|---|---|---|---|
| Mr. Stephane Bancel | CEO & Director | 4,55M | 300,71M | 1973 |
| Dr. Stephen Hoge M.D. | President | 1,92M | S.O. | 1977 |
| Mr. James M. Mock | Chief Financial Officer | 1,4M | S.O. | 1977 |
| Ms. Shannon Thyme Klinger | Chief Legal Officer & Corporate Secretary | 1,39M | S.O. | 1971 |
| Dr. Jerh Collins Ph.D. | Chief Technical Operations & Quality Officer | S.O. | S.O. | 1967 |
| Mr. Brad Miller | Chief Information Officer | S.O. | S.O. | 1974 |
| Ms. Lavina Talukdar CFA | Senior VP & Head of Investor Relations | S.O. | S.O. | S.O. |
| Colleen Hussey | Senior Director of Corporate Communications | S.O. | S.O. | S.O. |
| Ms. Tracey Franklin | Chief Human Resources Officer | S.O. | S.O. | 1981 |
| Dr. Melanie Ivarsson M.B.A., Ph.D. | Chief Development Officer | S.O. | S.O. | S.O. |
Description
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Gouvernance d’entreprise
L’ISS Governance QualityScore de Moderna, Inc. en date du 1 avril 2024 est 10. Les scores principaux sont Audit : 9; Société : 9; Droits des actionnaires : 10; Compensation : 9.
